Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945139 · ClinicalTrials.gov registry record · Phase 2
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00945139 is a Phase 2 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 46 participants.
The verdict
NCT00945139, a Phase 2 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin). How Doxil is metabolized and excreted from the body will also be studied.
Interventions
- DRUG Doxil
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00945139
The ClinicalTrials.gov registry entry for NCT00945139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxil is the first listed.
NCT00945139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00945139 about?
NCT00945139 is a clinical study titled "Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)". The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin). How Doxil is metabolized and excreted from the body will also be studied.
What is the current status of trial NCT00945139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2007-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00945139?
The interventions under investigation include: Doxil (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00945139?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.